Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Gross Profit: 2019-2025

Historic Gross Profit for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $9.7 million.

  • Beam Therapeutics' Gross Profit fell 32.03% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.7 million, marking a year-over-year decrease of 84.07%. This contributed to the annual value of $63.5 million for FY2024, which is 83.18% down from last year.
  • Beam Therapeutics' Gross Profit amounted to $9.7 million in Q3 2025, which was up 14.55% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Gross Profit registered a high of $316.2 million during Q4 2023, and its lowest value of $6,000 during Q1 2021.
  • Its 3-year average for Gross Profit is $42.4 million, with a median of $14.3 million in 2024.
  • Its Gross Profit has fluctuated over the past 5 years, first soared by 851,050.00% in 2021, then crashed by 90.49% in 2024.
  • Over the past 5 years, Beam Therapeutics' Gross Profit (Quarterly) stood at $51.1 million in 2021, then crashed by 60.76% to $20.0 million in 2022, then surged by 1,478.04% to $316.2 million in 2023, then crashed by 90.49% to $30.1 million in 2024, then slumped by 32.03% to $9.7 million in 2025.
  • Its last three reported values are $9.7 million in Q3 2025, $8.5 million for Q2 2025, and $7.5 million during Q1 2025.